| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Sorrento Therapeutics Inc. | Abivertinib - (MAVERICK) | Metastatic Castrate Resistant Prostate Cancer | Phase 2 | Oral | Oncology | |
| Sorrento Therapeutics Inc. | STI-2099 - (COVI-DROPS) | COVID-19 | Phase 2 | Intranasal | COVID-19 | |
| Sorrento Therapeutics Inc. | COVI-MSC (MSC-COV-202BR) | COVID-19 / Acute Respiratory Distress Syndrome | Phase 2 | Intravenous | COVID-19 | |
| Sorrento Therapeutics Inc. | Resiniferatoxin (RTX) - (OAK) | OsteoArthritis (OA) Knee Pain | Phase 2 | Intrathecal | Orthopedic | |
| Sorrento Therapeutics Inc. | Resiniferatoxin | Intractable Pain Associated with Cancer | Phase 2 | Intrathecal | Opioid Analgesic | |
| Sorrento Therapeutics Inc. | STI-3031 | Urothelial carcinoma | Phase 2a | oral | Oncology | |
| Spero Therapeutics Inc. | Tebipenem HBr (SPR994) - (PIVOT-PO) | Complicated urinary tract infection (cUTI), including acute pyelonephritis (AP) | NDA Filing | Ongoing | Oral | Antibiotic |
| Spero Therapeutics Inc. | Tebipenem HBr (SPR994) - (ADAPT-PO) | Complicated urinary tract infections (cUTI) | Phase 3 | Withdrawn | Oral | N/A |